scholarly journals NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors

2013 ◽  
Vol 4 (3) ◽  
pp. e560-e560 ◽  
Author(s):  
X Zhou ◽  
D Hollern ◽  
J Liao ◽  
E Andrechek ◽  
H Wang
2014 ◽  
Vol 369 (1633) ◽  
pp. 20130136 ◽  
Author(s):  
Adam J. Granger ◽  
Roger A. Nicoll

This review focuses on the research that has occurred over the past decade which has solidified a postsynaptic expression mechanism for long-term potentiation (LTP). However, experiments that have suggested a presynaptic component are also summarized. It is argued that the pairing of glutamate uncaging onto single spines with postsynaptic depolarization provides the final and most elegant demonstration of a postsynaptic expression mechanism for NMDA receptor-dependent LTP. The fact that the magnitude of this LTP is similar to that evoked by pairing synaptic stimulation and depolarization leaves little room for a substantial presynaptic component. Finally, recent data also require a revision in our thinking about the way AMPA receptors (AMPARs) are recruited to the postsynaptic density during LTP. This recruitment is independent of subunit type, but does require an adequate reserve pool of extrasynaptic receptors.


Biomolecules ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 1134 ◽  
Author(s):  
Tetsuro Kikuchi

Memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist approved for treating Alzheimer’s disease, has a good safety profile and is increasingly being studied for possible use in a variety of non-dementia psychiatric disorders. There is an abundance of basic and clinical data that support the hypothesis that NMDA receptor hypofunction contributes to the pathophysiology of schizophrenia. However, there are numerous randomized, double-blind, placebo-controlled clinical trials showing that add-on treatment with memantine improves negative and cognitive symptoms, particularly the negative symptoms of schizophrenia, indicating that memantine as adjunctive therapy in schizophrenia helps to ameliorate negative symptoms and cognitive deficits. It remains unclear why memantine does not show undesirable central nervous system (CNS) side effects in humans unlike other NMDA receptor antagonists, such as phencyclidine and ketamine. However, the answer could lie in the fact that it would appear that memantine works as a low-affinity, fast off-rate, voltage-dependent, and uncompetitive antagonist with preferential inhibition of extrasynaptic receptors. It is reasonable to assume that the effects of memantine as adjunctive therapy on negative symptoms and cognitive deficits in schizophrenia may derive primarily, if not totally, from its NMDA receptor antagonist activity at NMDA receptors including extrasynaptic receptors in the CNS.


1993 ◽  
Author(s):  
Kenneth M. Johnson ◽  
Lawrence D. Snell ◽  
Susan M. Jones ◽  
Aida I. Sacaan

1998 ◽  
Author(s):  
Irina Belozertseva ◽  
Anton Bespalov ◽  
Eugeny Gmiro ◽  
Wojciech Danysz ◽  
Edwin Zvartau

Sign in / Sign up

Export Citation Format

Share Document